Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

CITE: Clinical Inference Tethered to Evidence - a Retrieve-and-verify Layer for AI Care Plans (CITE)

16. juli 2026 opdateret af: Sanjay Basu, Waymark

A Randomized Controlled Trial of CITE (Clinical Inference Tethered to Evidence), an Evidence-Grounding Retrieve-and-Verify Layer That Flags Unsupported and Inappropriate Recommendations in AI-Generated Care Plans, Versus AI With Safety Guardrails Alone and Unassisted Care, in Medicaid Primary Care

This trial evaluates CITE, a retrieve-and-verify layer that audits an AI-generated care plan against a full-text evidence corpus and flags patient-specific codifiable safety hazards to the clinician. The co-primary outcomes are how accurately CITE flags these hazards (sensitivity and specificity versus blinded clinician adjudication) and its clinician alert burden and acceptance, compared with AI care plans using safety guardrails alone and with unassisted clinician care, in Medicaid primary care.

Studieoversigt

Detaljeret beskrivelse

Patients are randomized 1:1:1 to (1) unassisted clinician care; (2) AI-generated care plan with safety guardrails; (3) AI-generated care plan with safety guardrails plus CITE. CITE audits the finalized plan against a frozen, versioned evidence corpus and returns physician-facing flags for patient-specific codifiable safety hazards (a recommended drug contraindicated by this patient's diagnosis or laboratory value; a drug-allergy conflict; a dropped high-risk medication; a guideline-indicated therapy omitted for an active diagnosis; a stated quantity refuted by the corpus), each with a verbatim quote and citation; the clinician retains decision authority. Randomization uses a deterministic HMAC permuted-block scheme; outcome assessors are blinded to arm. The co-primary outcomes are (1) the diagnostic accuracy (sensitivity and specificity) of CITE against blinded clinician adjudication, and (2) clinician alert burden (flags per encounter) and acceptance, comparing the CITE arm with the guardrail arm; both are estimable at the enrolled sample size because they do not depend on a rare between-arm event. The unresolved codifiable-hazard rate by arm is reported as a descriptive secondary: codifiable hazards are infrequent, so the trial is not powered for a between-arm efficacy contrast on hazard reduction. A prior trial of a different mechanism (a generic deterministic rule-corpus that surfaced roughly 30 or more flags per encounter and was uninformative) was completed with null results and is registered separately; this trial evaluates a materially different, patient-specific intervention and set of outcomes. Determined exempt by WCG IRB (low risk). Analysis is pre-registered on OSF (https://doi.org/10.17605/OSF.IO/ENXCW).

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

240

Fase

  • Ikke anvendelig

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

INCLUSION CRITERIA:

  1. Age 18 years or older.
  2. Medicaid-enrolled and attributed to a participating Waymark primary care site.
  3. Primary care encounter that requires clinical reasoning (not administrative-only).
  4. English-language clinical documentation.

EXCLUSION CRITERIA:

  1. Age less than 18 years.
  2. Hospice or palliative-care-exclusive care plan.
  3. Administrative-only or pharmacy-only encounter that does not surface a clinical decision to the supervising clinician.
  4. Encounter where the supervising clinician is the principal investigator.
  5. Enrollment in a competing AI-safety study within the prior 90 days.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Sundhedstjenesteforskning
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Ingen indgriben: Arm 1: Unassisted care
Clinician develops the care plan without AI assistance.
Aktiv komparator: Arm 2: AI with safety guardrails
AI-generated care plan produced with a safety-guardrail system prompt; no CITE.
AI-generated care plan produced under a safety-guardrail system prompt.
Eksperimentel: Arm 3: AI with safety guardrails plus CITE
AI-generated care plan with safety guardrails, then passed through CITE, which flags unsupported/inappropriate recommendations with evidence citations for the clinician.
AI-generated care plan produced under a safety-guardrail system prompt.
Reads the AI care-plan text and verifies each recommendation/claim against a full-text evidence corpus; returns physician-facing flags (commission/confabulation/unsupported/omission) with verbatim quotes and citations. Clinician retains decision authority.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Diagnostic accuracy of CITE against clinician adjudication
Tidsramme: Day 1 (index primary care encounter)
Sensitivity and specificity (with positive and negative predictive values) of the CITE checker for clinically consequential codifiable safety hazards, using blinded clinician adjudication of the plan as the reference standard. Every plan contributes, so the estimate does not depend on a rare between-arm event. Exact-binomial 95% confidence intervals; reported overall and by hazard family.
Day 1 (index primary care encounter)
Clinician alert burden (flags surfaced per encounter)
Tidsramme: Day 1 (index primary care encounter)
Number of safety flags surfaced to the clinician per encounter in the CITE arm versus the guardrail arm, with clinician acceptance rate. Co-primary usability outcome: a verifier that surfaces an unmanageable number of flags is not deployable regardless of sensitivity (the prior-trial mechanism surfaced a median of about 30 per encounter). Pre-registered acceptability ceiling: median CITE flags per encounter at or below three.
Day 1 (index primary care encounter)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Clinician action on CITE flags
Tidsramme: Day 1 (index primary care encounter)
Proportion of CITE flags accepted vs overridden by the clinician, by flag type (commission, confabulation, unsupported, omission).
Day 1 (index primary care encounter)
Unresolved codifiable safety-hazard rate by arm (descriptive)
Tidsramme: Day 1 (index primary care encounter)
Proportion of patient-specific codifiable-hazard checkpoints with an unresolved hazard in the finalized plan, by arm, with the Arm 3 minus Arm 2 difference and 95% confidence interval. Pre-specified as descriptive and hypothesis-generating: codifiable hazards are infrequent, so the trial is not powered for a between-arm efficacy contrast on this measure at the enrolled sample size.
Day 1 (index primary care encounter)
Correction of codifiable hazards within 30 days
Tidsramme: Up to 30 days after the index encounter
Among checkpoints with a hazard in the finalized plan, the proportion acted on and corrected within 30 days (documented resolution, completed referral, or corrected order). Proximal clinical effectiveness measure.
Up to 30 days after the index encounter
Completed referrals within 30 days
Tidsramme: Up to 30 days after the index encounter
Proportion of initiated referrals completed within 30 days.
Up to 30 days after the index encounter
Clinical safety composite (exploratory)
Tidsramme: Day 1 (index primary care encounter)
Four-component clinical safety composite carried from the prior trial. Pre-specified as exploratory; underpowered at the planned sample size.
Day 1 (index primary care encounter)
30-day acute care utilization (exploratory)
Tidsramme: Up to 30 days after the index encounter
Emergency department visits and hospitalizations within 30 days. Exploratory.
Up to 30 days after the index encounter

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. september 2026

Primær færdiggørelse (Anslået)

1. juni 2027

Studieafslutning (Anslået)

1. september 2027

Datoer for studieregistrering

Først indsendt

13. juli 2026

Først indsendt, der opfyldte QC-kriterier

16. juli 2026

Først opslået (Faktiske)

22. juli 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

22. juli 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. juli 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • CITE-2026-02

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Patientsikkerhed

Abonner